Bone Solutions (BSI) signed an exclusive 10-state U.S. distribution agreement with Next Health for OsteoCrete magnesium-based bone graft substitute.
BSI is positioned to launch OsteoCrete this summer for U.S. and ex-U.S. extremities markets, and will pursue additional FDA clearance for spinal, dental and craniomaxillofacial applications once OsteoCrete is launched in the general orthopaedic and extremities market.
Source: Bone Solutions, Inc.
Some background on the OsteoCrete product:
In 2004, the magnesium-based, bioabsorbable adhesive compound demonstrated the ability to adhere bone and tendon within bone tunnels sufficiently to significantly augment anterior cruciate ligament reconstruction. In 2005, the company launched in vivo studies to affirm indications of bone formation following its use.
In 2009, BSI received FDA 510(k) clearance for OsteoCrete for use in the pelvis and long bones.
Bone Solutions (BSI) signed an exclusive 10-state U.S. distribution agreement with Next Health for OsteoCrete magnesium-based bone graft substitute.
BSI is positioned to launch OsteoCrete this summer for U.S. and ex-U.S. extremities markets, and will pursue additional FDA clearance for spinal, dental and craniomaxillofacial applications once...
Bone Solutions (BSI) signed an exclusive 10-state U.S. distribution agreement with Next Health for OsteoCrete magnesium-based bone graft substitute.
BSI is positioned to launch OsteoCrete this summer for U.S. and ex-U.S. extremities markets, and will pursue additional FDA clearance for spinal, dental and craniomaxillofacial applications once OsteoCrete is launched in the general orthopaedic and extremities market.
Source: Bone Solutions, Inc.
Some background on the OsteoCrete product:
In 2004, the magnesium-based, bioabsorbable adhesive compound demonstrated the ability to adhere bone and tendon within bone tunnels sufficiently to significantly augment anterior cruciate ligament reconstruction. In 2005, the company launched in vivo studies to affirm indications of bone formation following its use.
In 2009, BSI received FDA 510(k) clearance for OsteoCrete for use in the pelvis and long bones.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
